March 19, 2025 — Intriguing observations on the effect of retatrutide on cancer progression in mice appeared Friday in NPJ Metabolic Health and Disease. Retatrutide is the first triple agonist to progress in clinical development for obesity. Lilly said recently that they expect to release phase three clinical trial data for it later this year – earlier than previously […]
January 22, 2025 — One of the most important shifts in the approach to obesity in recent years has been an increased focus on the lived experience with this disease. One result has been the identification of food noise as a subjective experience that greatly affects the quality of life for many people living with obesity. Now, new research […]
November 2, 2024 — As we travel to San Antonio for ObesityWeek 2024 (OW2024) one of the principal threads we want to explore is the expanding scope of GLP-1 therapy benefits. The narrative is a moving target. We won’t have the abstracts in hand for another day. But news this week makes it clear that we have barely gotten […]
August 13, 2024 — For the second time in the past few months, a signal from the surveillance of GLP-1 agonists is surfacing to suggest that these drugs may offer a risk reduction strategy for cancer. Earlier, the signal came from a study of persons receiving treatment for diabetes. The present study, presented at the recent annual meeting for […]
August 24, 2023 — Let’s start with a few simple facts. Obesity causes cancer. Not every kind of cancer, but for at least a dozen types of cancer, obesity can clearly play a causal role. Scientists attribute between four and eight percent of all cancers to obesity. It is also true that, for now, the most effective single treatment […]
